Influence of CYP 3A5*3 genetic polymorphism on tacrolimus pharmacokinetics in renal transplant recipients

Objective To investigate the association between CYP 3A5*3 genetic polymorphism and tacrolimus dose-adjusted concentration at 2 hours after administration (C2/dose). Methods CYP 3A5*3 genotype were analyzed by polymerase chain reaction restriction fragment length polymorphism in 61 Chinese renal transplant recipients receiving tacrolimus. Microparticle enzyme immunoassay was used to measure the whole blood concentration of tacrolimus. Tacrolimus dosage,C2 and C2/dose were determined at 1 week, 1 month, and 3 months after transplantation.Results There was no significant difference of tacrolimus dosage between CYP 3A5*1/*1+CYP 3A5*1/*3 group and CYP 3A5*3/*3 group. At 1 week and 1 month after transplantation, tacrolimus C2 did not show significant difference between the two groups, while at 3 months after transplantation,C2 of CYP 3A5*1/*1+ CYP 3A5*1/*3 group and is significantly lower than the CYP 3A5*3/*3 group(P0.05).C2/dose of CYP 3A5*1/*1+ CYP 3A5*1/*3 group at 1 week, 1 month and 3 months after transplantation were significantly lower than CYP 3A5*3/*3 group (P0.05).Conclusion In renal transplantation, the tacrolimus C2/dose was associated with the CYP 3A5*3 genetic polymorphism.